Login Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

  • Watchlist

    Keep track of companies that you follow and research.

  • 10 Years of Data

    Full access to our data with predictions and indicators that we calculate daily.

  • Screener

    Full access to our screener with tons of custom values and customizable email notifications.

  • XLS Exports

    Excel export of financials and screeners you define and save.

Subscribe now
Screener Weekly Summary

Amgen Inc. AMGN

Healthcare  —  Drug Manufacturers General
S&P 500 Member Dividend Champion (3y)
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years
Overview Business Profile Analyst Commentary Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Amgen Inc. (AMGN) Business Profile

Company Overview

Amgen Inc. (AMGN) is a leading global biotechnology company headquartered in Thousand Oaks, California. Founded in 1980, Amgen has grown to become one of the largest independent biotechnology firms in the world. The company was originally established as Applied Molecular Genetics and later rebranded to Amgen. Its mission is to serve patients by leveraging science and innovation to develop transformative medicines.

Amgen’s leadership team is composed of experienced professionals who drive the company’s strategic vision. Robert A. Bradway serves as the Chairman and Chief Executive Officer (CEO). Under his leadership, Amgen has expanded its global footprint and strengthened its position in the biotechnology sector. Other key executives include Peter H. Griffith, Executive Vice President and Chief Financial Officer, and David M. Reese, M.D., Executive Vice President of Research and Development.

Core Business Segments

Amgen operates across several core business segments, focusing on innovative therapies that address serious illnesses. The company’s primary product categories include:

1. Oncology and Hematology

Amgen is a leader in developing therapies for cancer and blood disorders. Key products in this segment include:

  • Kyprolis® (carfilzomib): A treatment for multiple myeloma.
  • Blincyto® (blinatumomab): A therapy for acute lymphoblastic leukemia (ALL).
  • Neulasta® (pegfilgrastim): A medication to reduce the risk of infection in patients undergoing chemotherapy.

2. Cardiovascular Health

Amgen has made significant strides in addressing cardiovascular diseases. Notable products include:

  • Repatha® (evolocumab): A cholesterol-lowering medication that helps reduce the risk of heart attacks and strokes.
  • Corlanor® (ivabradine): A treatment for chronic heart failure.

3. Inflammation and Bone Health

Amgen offers therapies for inflammatory diseases and bone-related conditions. Key products include:

  • Enbrel® (etanercept): A treatment for rheumatoid arthritis, psoriatic arthritis, and other inflammatory conditions.
  • Prolia® (denosumab): A medication for osteoporosis.
  • Evenity® (romosozumab-aqqg): A treatment for osteoporosis in postmenopausal women at high risk of fracture.

4. Biosimilars

Amgen has a growing portfolio of biosimilars, which are biologic medical products highly similar to already approved reference products. Examples include:

  • Mvasi® (bevacizumab-awwb): A biosimilar to Avastin®.
  • Kanjinti® (trastuzumab-anns): A biosimilar to Herceptin®.

5. Other Therapeutic Areas

Amgen also develops treatments for rare diseases and other conditions. For example:

  • Aimovig® (erenumab-aooe): A preventive treatment for migraines.

Business Model

Amgen’s business model is centered on innovation, research, and development (R&D). The company invests heavily in R&D to discover and develop new therapies. Amgen integrates its products and services by focusing on biologics, which are complex molecules derived from living cells. The company generates revenue through the sale of its proprietary medicines, biosimilars, and licensing agreements.

Amgen also emphasizes operational efficiency and cost management. The company leverages advanced manufacturing technologies and a global supply chain to ensure the availability of its products worldwide. Additionally, Amgen collaborates with healthcare providers, payers, and policymakers to improve patient access to its therapies.

Strategic Direction

Amgen’s strategic direction is guided by its commitment to innovation and patient-centric care. Key elements of its future plans include:

  • Pipeline Expansion: Amgen is focused on advancing its pipeline of investigational therapies. The company is exploring new treatment areas, including oncology, cardiovascular health, and rare diseases.
  • Sustainability Goals: Amgen has set ambitious sustainability targets, such as achieving carbon neutrality by 2027 and reducing water usage and waste generation.
  • Global Expansion: The company aims to expand its presence in emerging markets and strengthen its position in established markets.
  • Digital Transformation: Amgen is leveraging digital technologies and data analytics to enhance its R&D capabilities and improve operational efficiency.

Competitive Landscape

Amgen operates in a highly competitive biotechnology and pharmaceutical industry. Key competitors include:

  • Roche: A global leader in oncology and diagnostics.
  • Pfizer: A major pharmaceutical company with a diverse portfolio of medicines and vaccines.
  • Novartis: Known for its innovative therapies in oncology, cardiology, and other areas.
  • Biogen: Specializes in treatments for neurological and neurodegenerative diseases.
  • Gilead Sciences: Focuses on antiviral therapies and oncology.

Amgen differentiates itself through its focus on biologics, biosimilars, and a robust R&D pipeline.

Risk Factors

Amgen faces several risks that could impact its business operations and financial performance. Key risks include:

  • Market Dependence: The company relies on a few key products for a significant portion of its revenue. Any decline in sales of these products could adversely affect its financial results.
  • Regulatory Challenges: The biotechnology industry is heavily regulated, and changes in regulatory policies could impact Amgen’s ability to bring new products to market.
  • Supply Chain Disruptions: Global supply chain issues, including raw material shortages and transportation challenges, could affect the availability of Amgen’s products.
  • Competition: Intense competition from other biotechnology and pharmaceutical companies could erode Amgen’s market share.
  • Intellectual Property Risks: The expiration of patents and the entry of generic or biosimilar competitors could impact revenue.

Recent Developments

Amgen has made several notable advancements in recent years:

  • Acquisitions: In 2022, Amgen acquired Five Prime Therapeutics to strengthen its oncology portfolio.
  • New Product Approvals: The company received regulatory approval for several new therapies, including Tezspire™ (tezepelumab-ekko) for severe asthma.
  • COVID-19 Response: Amgen contributed to the global fight against COVID-19 by supporting vaccine development and ensuring the supply of critical medicines.
  • Sustainability Initiatives: Amgen launched its “Environmental Sustainability Plan” to achieve carbon neutrality and reduce its environmental footprint.

Investment Considerations

Investors considering Amgen should weigh the following strengths and risks:

Strengths:

  • Strong portfolio of innovative therapies.
  • Robust R&D pipeline with potential for future growth.
  • Global presence and operational efficiency.
  • Commitment to sustainability and corporate responsibility.

Risks:

  • Dependence on key products for revenue.
  • Regulatory and competitive pressures.
  • Potential supply chain disruptions.
  • Patent expirations and biosimilar competition.

Conclusion

Amgen Inc. is a leading biotechnology company with a strong track record of innovation and patient-centric care. The company’s diverse portfolio, robust R&D pipeline, and commitment to sustainability position it well for future growth. While Amgen faces challenges such as regulatory pressures and competition, its strategic initiatives and focus on operational excellence make it a compelling player in the biotechnology industry.